Skip to content

Xencor XNCR EV / sales

EV / sales at other companies

Amgen logo
AmgenAMGN
6.6×+0.1×
Regeneron Pharmaceuticals logo
Regeneron PharmaceuticalsREGN
5.5×+0.6×
Janux Therapeutics logo
Janux TherapeuticsJANX
59.4×-106×
AbCellera Biologics Inc. logo
AbCellera Biologics Inc.ABCL
13.8×-9.9×
AnaptysBio, Inc. logo
AnaptysBio, Inc.ANAB
5.8×+1.4×
Xenon Pharmaceuticals logo
Xenon PharmaceuticalsXENE
436.3×

Other financials

Income statement

See full
Revenue$4.5M-86.2%
Operating income-$77.9M-80.3%
Net income-$128.9M-166%
EPS (diluted)-$1.71-159%

Balance sheet

See full
Cash & equivalents$14.2M-64.3%
Total debt$175.2M-21.2%
Total equity$515.6M-19.4%
Total assets$736.8M-18.6%

Cash flow

See full
Operating cash flow-$67.6M-317%
CapEx$610.0K-57.8%
Free cash flow-$68.2M-286%

Valuation

See full
Market cap$1.07B+79.8%
Enterprise value$1.23B+58.6%
P/S11×+6.3×

Profitability

See full
Operating margin-217.9%+425pp
Net margin-177.1%+16.5pp
FCF margin-194%+166pp

Returns & leverage

See full
Return on equity-29.8%-2.7pp
Debt / equity0.3×0.0×
Current ratio6.6×+0.7×

Where this comes from

Calculated from Xencor’s reported figures.

Based on the most recent quarter.

The official record: Xencor’s 10-Q, filed May 6, 2026, on SEC EDGAR. View the filing →

Ask your AI about Xencor's ev / sales.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Xencor's EV / sales?
Xencor (XNCR) reported EV / sales of 10.7× in Q1 2026.
How has Xencor's EV / sales changed year-over-year?
Xencor's EV / sales increased by 46.5% year-over-year, from 7.3× to 10.7×.
What is the long-term trend for Xencor's EV / sales?
Over 5 years (2020 to 2025), Xencor's EV / sales has grown at a -13.0% compound annual growth rate (CAGR), from 19.6× to 9.8×.
What does EV / sales mean?
Enterprise value at the quarter end divided by trailing-twelve-month revenue. A capital-structure-neutral revenue multiple, useful when earnings are negative.